In a recent article featured in In Vivo, the CEO of Albus Health, Mikesh Udani, explores why nighttime physiology is still under‑represented in clinical evidence, and how that is beginning to change.

Overnight symptoms across respiratory, neurological, paediatric and cardiometabolic disease remain largely invisible to tools like diaries, morning recall and sleep‑lab assessments. Yet these signals often reflect treatment response, risk and disease biology.

The op‑ed highlights three shifts now reshaping evidence generation:
● Improvements in sleep and nighttime symptoms are emerging as a meaningful dimension of treatment response.
● Objective nighttime data is now achievable at scale. Entire nights of physiology no longer need to be compressed into a single morning entry.
● Passive, contactless remote monitoring is moving upstream into core study design.

The piece also points to the growing value of early‑warning signals such as passive detection of respiratory deterioration days before symptoms appear. This has implications far beyond respiratory disease, from oncology safety monitoring to neurological progression.

Read the full commentary here.